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We evaluated the efﬁcacy and tolerability of Hachimi-jio-gan (HJG;八味地黃丸 ba wei dì huang wan) and
Gosha-jinki-gan (GJG; 濟生腎氣丸 jì sheng shen qì wan), two traditional Japanese medicines, in 60 pa-
tients with lower urinary tract symptoms (LUTS) having cold sensitivity unresponsive to a1-blockers or
antimuscarinic drugs. All patients received a mixture of HJG or GJG for 12 weeks in addition to a1-
blockers or antimuscarinic drugs as add-on therapy. International Prostate Symptom Score, Interna-
tional Prostate Symptom ScoreeQuality of Life, Benign Prostatic Hyperplasia Impact Index, and the
number of nocturnal voids were statistically much improved. However, there was no change in maximal
urinary ﬂow rate and post-void residual urine. Urinary 8-hydroxy-2-deoxyguanosine was statistically
greatly improved from baseline after treatment in the HJG group compared to the GJG group. Adverse
reactions were observed in 8.3% of patients, but all reactions were mild. Both HJG and GJG mixtures can
serve as safe and effective potential therapeutic alternatives in patients with LUTS and cold sensitivity
unresponsive to a1-blockers or antimuscarinic drugs. Additionally, HJG mixture was found to have anti-
oxidative activity, and therefore further long-term clinical investigations are needed to examine its anti-
aging effects in addition to its effect on urinary symptoms.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of lower urinary tract symptoms (LUTS) gradually
increases with age, greatly affecting quality of life (QOL).1 Treat-
ment options for LUTS range from behavioral modiﬁcation, such as
bladder training, to medical treatment. Antimuscarinic agents and
a1-blockers are the most frequently prescribed drug options, but in
Japan, complex formulations of Japanese traditional herbal medi-
cines have been widely used and empirically evaluated in patients
with LUTS and cold sensitivity.2 Recent animal studies have
revealed that Hachimi-jio-gan (HJG; 八味地黃丸 ba wei dì huang
wan) and Gosha-jinki-gan (GJG; 濟生腎氣丸 jì sheng shen qì wan)Dokkyo Medical University




for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).increased bladder capacity and decreased frequency of distension-
induced bladder contractions via the spinal kappa-opioid receptor.3
Previous clinical studies have demonstrated the efﬁcacy of HJG and
GJG, frequently in conjunction with antimuscarinic agents or a1-
blockers, for treating LUTS.4
Although LUTS has various symptoms, we have focused on cold
sensitivity, a key indication in Japanese traditional herbal medicine.
In the present study, we attempted to determine the efﬁcacy and
safety of HJG and GJG as an add-on therapy for patients with LUTS
and cold sensitivity, unresponsive to a1-blockers or antimuscarinic
drugs by using the International Prostate Symptom Score (IPSS),
IPSS-Quality of Life (IPSS-QOL), Benign Prostatic Hyperplasia
Impact Index (BII), uroﬂowmetry (UFM), frequency volume chart
(FVC), and urinary 8-hydroxy-20-deoxyguanosine (8-OHdG).
2. Materials and methods
2.1. Safety analysis
Before commencing the study, we obtained approval from our
institution's ethical review board and obtained written informedrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
Table 1
Clinical characteristics of the 60 patients.
HJG GJG P value#
Age (years) 74.7 ± 6.2 75.5 ± 5.1 0.142
Sex (M/F) 23/7 24/6
IPSS Total score 13.4 ± 5.2 14.5 ± 6.2 0.182
Storage score 6.4 ± 2.3 8.1 ± 2.9 0.014
Voiding score 7.0 ± 4.1 6.4 ± 4.6 0.974
QOL 3.4 ± 1.4 4.2 ± 1.2 0.028
BII 4.4 ± 2.6 6.3 ± 4.1 0.055
UFM PVR (ml) 36.1 ± 35.2 26.1 ± 26.7 0.362
Qmax (ml/s) 10.9 ± 5.6 10.7 ± 10.1 0.793
Nocturnal voids (times) 2.8 ± 1.0 4.4 ± 1.3 <0.001
8-OHdG (ng/ml creatinine) 17.2 ± 5.8 16.9 ± 10.7 0.725
HJG¼Hachimi-jio-gan.
GJG ¼ Gosha-jinki-gan.
IPSS¼ International Prostate Symptom Score.
QOL ¼ quality of life.
BII ¼ benign prostatic hyperplasia impact index.
UFM ¼ uroﬂowmetry.
PVR ¼ post-void residual urine.
Qmax ¼ maximum ﬂow rate.
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine.
#Wilcoxon's signed rank test (p < 0.05 was considered signiﬁcant).
Table 2
Effects of HJG on LUTS resistant to a1 blockers and antimuscarinic drugs.
Baseline After 12 weeks P value#
IPSS Total score 13.4 ± 5.2 9.7 ± 5.1 <0.001
Storage score 6.4 ± 2.3 4.7 ± 2.3 <0.001
Voiding score 7.0 ± 4.1 4.9 ± 3.4 0.008
QOL 3.4 ± 1.4 2.6 ± 1.3 0.014
BII 4.4 ± 2.6 2.9 ± 1.9 0.021
UFM PRV (ml) 36.1 ± 35.2 37.2 ± 29.4 0.935
Qmax (ml/s) 10.9 ± 5.6 9.8 ± 4.6 0.361
Nocturnal voids (times) 2.8 ± 1.0 2.2 ± 1.1 0.005
8-OHdG (ng/ml creatinine) 17.2 ± 5.8 12.3 ± 4.1 0.001
HJG¼Hachimi-Jio-gan.
LUTS ¼ lower urinary tract symptoms.
IPSS¼ International Prostate Symptom Score.
QOL ¼ quality of life.
BII ¼ benign prostatic hyperplasia impact index.
PVR ¼ post-void residual urine.
Qmax ¼ maximum ﬂow rate.
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine.
#Student's t-test (p < 0.05 was considered signiﬁcant).
Table 3
Effects of GJG on LUTS resistant to a1 blockers and antimuscarinic drugs.
Baseline After 12 W P Value#
IPSS Total score 14.5 ± 6.2 10.4 ± 3.9 <0.001
Storage score 8.1 ± 2.9 6.1 ± 2.0 0.003
Voiding score 6.4 ± 4.6 4.3 ± 3.2 0.012
QOL 4.2 ± 1.2 3.3 ± 1.5 0.007
BII 6.3 ± 4.1 5.0 ± 3.4 0.024
UFM PVR(ml) 26.1 ± 26.7 24.2 ± 23.4 0.821
Qmax (ml/s) 10.7 ± 10.0 10.3 ± 8.2 0.802
Nocturnal voids (times) 4.4 ± 1.3 3.5 ± 1.9 0.008
8-OHdG (ng/ml creatinine) 16.9 ± 10.5 14.8 ± 6.5 0.241
GJG ¼ Gosha-jinki-gan.
IPSS¼ International Prostate Symptom Score.
QOL ¼ quality of life.
BII ¼ benign prostatic hyperplasia impact index.
UFM ¼ uroﬂowmetry.
PVR ¼ post-void residual urine.
Qmax ¼ maximum ﬂow rate.
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine.
#Student's t-test (p < 0.05 was considered signiﬁcant).
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cacy and possible adverse reactions of HJG (八味地黃丸 ba wei dì
huang wan) and GJG (濟生腎氣丸 jì sheng shen qì wan) mixture.
2.2. Hachimi-jio-gan and Gosha-jinki-gan
HJG (TJ-7; Tsumura Co., Tokyo, Japan) is the extract product
which included 4.0 g of the compound extracts of 8 herbal medi-
cines: Rehmanniae radix (地黃 dì huang) (6.0 g), Corni fructus (山茱
萸 shan zhu yú) (3.0 g), Dioscoreae rhizoma (山藥 shan yao) (3.0 g),
Hoelen (茯苓 fú ling) (3.0 g), Alismatis rhizoma (澤瀉 ze xie) (3.0 g),
Moutan cortex (牡丹皮 mǔ dan pí) (2.5 g), Cinnamoni cortex (桂皮
guì pí) (1.0 g) and heat-proscessed Aconiti radix (附子 fù zǐ) (0.5 g).
On the other hand, GJG (TJ-107; Tsumura Co., Tokyo, Japan) includes
4.5 g of the compound extracts of 10 herbal medicines: Rehmanniae
radix (5.0 g), Achyranthis radix (牛膝 niú xı) (3.0 g), Corni fructus
(3.0 g), Dioscoreae rhizoma (3.0 g), Hoelen (3.0 g), Plantaginis
semen (車前子 che qian zǐ) (3.0 g), Alismatis rhizoma (3.0 g),
Moutan cortex (3.0 g), Cinnamoni cortex (1.0 g) and heat-
proscessed Aconiti radix (1.0 g). They are standaedized spray-
dried water extracts, which include magnesium stearate, lactose
and fructose fatty acid esters as diluents. The manufacturing pro-
cess meets all requirements of the Japanese and international GMP
guidelines.
2.3. Eligibility and study design
Patients who visited our hospital with LUTS for consultation
between November 2012 and May 2014 were considered for
enrollment. The inclusion criteria were as follows: age 60 years or
older; IPSS total score of 8 or more points despite treatment with
a1-blockers or antimuscarinic drugs for at least 4 weeks; IPSS-QOL
score of 3 or more points; subjective complaints such as cold hands
and/or legs even in a warm environment. Patients with any com-
plications possibly affect the voiding function, such as neurogenic
bladder, urethral stricture, and active urinary tract infection, were
excluded.
The study was designed as an open, non-randomized, two-
armed study comparing two Japanese traditional herbal medicines
for treating LUTS. All patients received 7.5 g/day HJG or GJGmixture
for 12 weeks as add-on therapy to a1-blockers or antimuscarinic
drugs. Blood cell count, standard chemistry panel, and urinalysis
were assessed routinely at the initial examination. IPSS, IPSS-QOL,
BII, 3-day FVC and UFM were examined before and after adminis-
tration. We evaluated urinary 8-OHdG levels as a marker of
oxidative stress using an ICR-001 device (The selling agency of ICR-
001 device is Selista Inc, Tokyo) according to the manufacturer's
recommendations.
2.4. Statistical analysis
Data are reported as mean ± SD. Data were analyzed using SPSS
software, version 12.0 (IBM, Chicago, IL). To evaluate the treatment
effect between before and after mediation, Wilcoxon's signed-rank
test was used to Tables 1 and 4. The other hand, Student's t-test was
used to Tables 2 and 3. P < 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of HJG (八味地黃丸 ba wei dì huang wan) and GJG (濟生
腎氣丸 jì sheng shen qì wan)
Clinical characteristics of the 60 patients are shown in Table 1.
Thirty patients (23 men and 7 women, aged 68e80 years, mean
74.7 ± 6.2) received HJG mixture and 30 (24 men and 6 women,
Table 4
Change from baseline after 12 weeks of treatment with HJG or GJG.
HJG GJG P Value#
IPSS Total score 2.6 ± 3.8 4.3 ± 4.3 0.113
Storage score 1.1 ± 1.7 2.1 ± 2.5 0.151
Voiding score 1.5 ± 3.3 2.2 ± 2.9 0.305
QOL 0.8 ± 1.4 0.9 ± 1.6 0.805
BII 1.6 ± 3.0 1.4 ± 3.1 0.909
UFM PVR (ml) 0.5 ± 44 1.4 ± 31 0.892
Qmax (ml/s) 1.0 ± 5.3 0.3 ± 7.0 0.703
Nocturnal voids (times) 0.6 ± 0.9 0.8 ± 1.16 0.388
8-OHdG (ng/ml creatinine) 5.7 ± 5.4 0.9 ± 5.1 0.017
HJG¼Hachimi-jio-gan.
GJG ¼ Gosha-jinki-gan.
IPSS¼International Prostate Symptom Score.
QOL ¼ quality of life.
BII ¼ benign prostatic hyperplasia impact index.
UFM ¼ uroﬂowmetry.
PVR ¼ post-void residual urine.
Qmax ¼ maximum ﬂow rate.
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine.
#Wilcoxon's signed rank test (p < 0.05 was considered signiﬁcant).
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IPSS score, BII, post-void residual urine (PVR), maximal urinary ﬂow
rate (Qmax), and urinary 8-OHdG did not signiﬁcantly differ be-
tween the HJG and GJG groups. However, IPSS storage subscore,
QOL and nocturnal voids were signiﬁcantly greater in the GJG
group.
Results of treatment with HJG are shown in Table 2. Signiﬁcantly
improved subjective outcomes were IPSS total and subscore, QOL,
and BII, and signiﬁcantly improved objective outcomes were fewer
nocturnal voids and lower urinary 8-OHdG. Other objective pa-
rameters such as Qmax and PVR did not improve. In the GJG group
(Table 3), signiﬁcantly improved subjective outcomes were IPSS
total and subscore, QOL, and BII. Although the number of nocturnal
voids decreased signiﬁcantly, other objective parameters, namely,
Qmax, PVR, and urinary 8-OHdG did not improve.
Table 4 presents the change from baseline after treatment. No
statistical signiﬁcant differences were found between the HJG and
GJG groups in terms of total IPSS score, IPSS subscore, QOL, BII, PVR,
Qmax, or number of nocturnal voids. However, there was a signif-
icantly larger decrease in urinary 8-OHdG in the HJG group
(5.7 ± 5.4) than in the GJG group (0.9 ± 5.1) (P ¼ 0.017).3.2. Safety and tolerability
Adverse reactions of HJG were observed in 2 men (6.7%). The
symptoms were gastric discomfort and nausea. On the other hand,
the adverse reactions of GJG were observed in 2 men and 1 woman
(10%). The symptoms were gastric discomfort in 2 patients and
nausea in one, and all such cases were of mild sevirity (grade 1) and
were followed up closely without therapy. No patients dis-
continued the treatment due to these adverse evevnts.4. Discussion
HJG (八味地黃丸 ba wei dì huang wan) and its modiﬁed pre-
scription GJG (濟生腎氣丸 jì sheng shen qì wan) are prescribed to
patients with edema in the lower extremities and LUTS with cold
sensitivity. The way by which HJG and GJG treat LUTS have
remained unclear, but resent basic research has gradually clariﬁed
these mechanisms.5e9 Gotoh et al.3 reported that the effects on
LUTS are associated with inhibition of the micturation reﬂex and
reduction of bladder sensation via spinal kappa-opioid receptors.7
Among the ingredients contained in these medicines, AconitiRhizhoma (附子 fù zǐ) from Aconitum carmichaelii may be mainly
responsible for the antinociceptive effect.9 In addition to the effect
of Aconiti Rhizhoma, Kupelian et al. hypothesized that other in-
gredients, such as Alismatis Rhizoma (澤瀉 ze xie) from Alisma
orientale and Poria (茯苓 fú ling) from Poria cocos, could be effective
for decreasing nocturnal urine production and thereby regulating
the distribution of ﬂuid in the body.10 In the present study, we
selected patients with LUTS unresponsive to both a1-blockers and
antimuscarinic drugs. We had a tendency of prescribing GJG for
patients with more edematous extremities, so that it is suggested
that IPSS storage subscore, QOL and nocturnal voids were signiﬁ-
cantly greater in the GJG group.
Some people have experience of “cool hands and/or legs (四肢冰
冷 sì zhı bıng leng)” even in awarm environment, without clinically
evident cardiovascular disease.11 These sensations are an indication
of cold sensitivity, an important concept in oriental medicine. By
comparing the cold stress rat model to control rats, Imamura et al.
reported that cold stress-induced detrusor overactivity is mediated
through a resiniferatoxin-sensitive C-ﬁber sensory nerve
pathway.12 In a separate study, Imamura et al. showed that HJG-
treated rats tended to have higher skin temperature during low-
temperature exposure and that their cold stress-induced detrusor
overactivity associated with increased micturition frequency and
decreased micturition volume was inhibited.13 In this study, we
didn't evaluate the relevance of LUTS and cold sensitivity by
continuous skin surface temperature measurement. However, our
ﬁndings in of improved subjective and objective outcomes for LUTS
are support these previous ﬁndings in the cold rat model.
Oxidative stress is reported to result in pathophysiological
conditions of the urinary bladder via damage to the urothelium and
sensitization of bladder afferent signaling.14 Previous studies have
shown that oxidative stress mediates capsaicin-sensitive C-ﬁbers to
induce bladder hyperactivity.15 Therefore, the elimination of
oxidative stress might ameliorate pathophysiological conditions in
the urinary bladder and be a possible therapy for LUTS unrespon-
sive to a1-blockers or antimuscarinic drugs.16,17 In the present
study, we found anti-oxidative effects of HJG but not GJG. The GJG
formula is a modiﬁcation of HJG formed by addition of Achyranthis
Radix (牛膝 niú xı) from Achyranthes fauriei and Plantaginis Semen
(車前子 che qian zǐ) from Plantago asiatica, yet there was no anti-
oxidative effect as indicated by production of 8-OHdG. The reason
for this is not clear from the present study, but recent studies have
revealed that Chinese medicinal herbs (CMHs; 中草藥 zhong cǎo
yao)indicate anti-oxidative effects to a living body by biological
response modiﬁer (BRM).18 Adding two herbal agents (Achyranthis
Radix and Plantaginis Semen) to HJG, BRM of HJG might be inﬂu-
enced to the anti-oxidative effects. Although anticholinergic agents
are presently most commonly used in the treatment of overactive
bladder, the anti-oxidant properties of HJG could have a therapeutic
role in the treatment of bladder hyperactivity.
The major drawbacks of this study are small number of patients,
lack of a placebo-controlled group, and lack urodynamic study data.
The possibility of a placebo effect may be high in LUTS, which has a
strong placebo component. Therefore, it remains unclear whether
HJG and GJG may be potential therapeutic alternatives in elderly
patients with LUTS and cold sensitivity unresponsive to a1-
blockers or antimuscarinic drugs. A future prospective evaluation
is necessary.
5. Conclusions
The HJG (八味地黃丸 ba wei dì huang wan) and GJG (濟生腎氣丸
jì sheng shen qì wan) Japanese herbal formulations might have the
potential to provide additional therapeutic effects in treating cold
stresseexacerbated LUTS resistant to a1-blockers or antimuscarinic
H. Yagi et al. / Journal of Traditional and Complementary Medicine 5 (2015) 258e261 261drugs. However, further clinical investigations are required to
elucidate their precise mechanisms.Conﬂict of interest
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